In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity

References

• Strobl B, Stoiber D, Sexl V, Mueller M. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci (Landmark Ed) 2011; 16:3214-32; PMID:21622231; http://dx.doi.org/10.2741/3908
   PubMed Web of Science ®Google Scholar
• Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, McCoy B, Bogdan C, Decker T, Brem G et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000; 13:549-60; PMID:11070173; http://dx.doi.org/10.1016/S1074-7613(00)00054-6
   PubMed Web of Science ®Google Scholar
• Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, Heutel JD, Dungo-Arthur C, Carrero JA, White JM, Hertzog PJ et al. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 2006; 26:804-19; PMID:17115899; http://dx.doi.org/10.1089/jir.2006.26.804
   PubMed Web of Science ®Google Scholar
• Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori M, Yamashita M, Numata A, Takase K, Kobayashi S et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000; 13:561-71; PMID:11070174; http://dx.doi.org/10.1016/S1074-7613(00)00055-8
   PubMed Web of Science ®Google Scholar
• Shaw MH, Boyartchuk V, Wong S, Karaghiosoff M, Ragimbeau J, Pellegrini S, Muller M, Dietrich WF, Yap GS. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci U S A 2003; 100:11594-9; PMID:14500783; http://dx.doi.org/10.1073/pnas.1930781100
   PubMed Web of Science ®Google Scholar
• Ubel C, Mousset S, Trufa D, Sirbu H, Finotto S. Establishing the role of tyrosine kinase 2 in cancer. Oncoimmunology 2013; 2:e22840; PMID:23482926; http://dx.doi.org/10.4161/onci.22840
   PubMed Web of Science ®Google Scholar
• Simma O, Zebedin E, Neugebauer N, Schellack C, Pilz A, Chang-Rodriguez S, Lingnau K, Weisz E, Putz EM, Pickl WF et al. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res 2009; 69:203-11; PMID:19118004; http://dx.doi.org/10.1158/0008-5472.CAN-08-1705
   PubMed Web of Science ®Google Scholar
• Zhang Q, Sturgill JL, Kmieciak M, Szczepanek K, Derecka M, Koebel C, Graham LJ, Dai Y, Chen S, Grant S et al. The role of Tyk2 in regulation of breast cancer growth. J Interferon Cytokine Res 2011; 31:671-7; PMID:21864028; http://dx.doi.org/10.1089/jir.2011.0023
   PubMed Web of Science ®Google Scholar
• Vielnascher RM, Hainzl E, Leitner NR, Rammerstorfer M, Popp D, Witalisz A, Rom R, Karaghiosoff M, Kolbe T, Muller S et al. Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance. Transgenic Res 2014; 23:519-29; PMID:24696087; http://dx.doi.org/10.1007/s11248-014-9795-y
   PubMed Web of Science ®Google Scholar
• Shimoda K, Tsutsui H, Aoki K, Kato K, Matsuda T, Numata A, Takase K, Yamamoto T, Nukina H, Hoshino T et al. Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood 2002; 99:2094-9; PMID:11877284; http://dx.doi.org/10.1182/blood.V99.6.2094
   PubMed Web of Science ®Google Scholar
• Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, Weisz E, Artwohl M, Kleine OC, Muller M et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 2004; 114:1650-8; PMID:15578097; http://dx.doi.org/10.1172/JCI200422315
   PubMed Web of Science ®Google Scholar
• Schleicher U, Mattner J, Blos M, Schindler H, Rollinghoff M, Karaghiosoff M, Muller M, Werner-Felmayer G, Bogdan C. Control of Leishmania major in the absence of Tyk2 kinase. Eur J Immunol 2004; 34:519-29; PMID:14768057; http://dx.doi.org/10.1002/eji.200324465
   PubMed Web of Science ®Google Scholar
• Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, Takada H, Hara T, Kawamura N, Ariga T et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25:745-55; PMID:17088085; http://dx.doi.org/10.1016/j.immuni.2006.09.009
   PubMed Web of Science ®Google Scholar
• Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, Kreins AY, Grant AV, Abel L, Casanova JL. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr 2012; 160:1055-7; PMID:22402565; http://dx.doi.org/10.1016/j.jpeds.2012.01.056
   PubMed Web of Science ®Google Scholar
• Ishizaki M, Muromoto R, Akimoto T, Sekine Y, Kon S, Diwan M, Maeda H, Togi S, Shimoda K, Oritani K et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol 2014; 26:257-67; PMID:24345760; http://dx.doi.org/10.1093/intimm/dxt062
   PubMed Web of Science ®Google Scholar
• Liang J, Tsui V, Van Abbema A, Bao L, Barrett K, Beresini M, Berezhkovskiy L, Blair WS, Chang C, Driscoll J et al. Lead identification of novel and selective TYK2 inhibitors. Eur J Med Chem 2013; 67:175-87; PMID:23867602; http://dx.doi.org/10.1016/j.ejmech.2013.03.070
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhu Y, Xia Y, Peng H, Yang XK, Liu YY, Xu WD, Pan HF, Ye DQ. Therapeutic potential of tyrosine kinase 2 in autoimmunity. Expert Opin Ther Targets 2014; 18:571-80; PMID:24654603; http://dx.doi.org/10.1517/14728222.2014.892925
   PubMed Web of Science ®Google Scholar
• Menet CJ. Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases. Pharm Pat Anal 2014; 3:449-66; PMID:25291316; http://dx.doi.org/10.4155/ppa.14.23
   PubMedGoogle Scholar
• Norman P. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum. Expert Opin Ther Pat 2014; 24:361-8; PMID:24386992; http://dx.doi.org/10.1517/13543776.2014.864637
   PubMed Web of Science ®Google Scholar
• Works MG, Song B, Kibler P, Tanga MJ, Galande AK, D'Andrea A. Design of a peptide inhibitor of tyrosine kinase 2. Protein Pept Lett 2014; 21:419-25; PMID:24304386; http://dx.doi.org/10.2174/0929866520666131203101841
   PubMed Web of Science ®Google Scholar
• Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov 2013; 3:564-77; PMID:23471820; http://dx.doi.org/10.1158/2159-8290.CD-12-0504
   PubMed Web of Science ®Google Scholar
• Velusamy T, Kiel MJ, Sahasrabuddhe AA, Rolland D, Dixon CA, Bailey NG, Betz BL, Brown NA, Hristov AC, Wilcox RA et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 2014; 124(25):3768-71; PMID:25349176; http://dx.doi.org/10.1182/blood-2014-07-588434
   PubMed Web of Science ®Google Scholar
• Ide H, Nakagawa T, Terado Y, Kamiyama Y, Muto S, Horie S. Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells. Biochem Biophys Res Commun 2008; 369:292-6; PMID:17920038; http://dx.doi.org/10.1016/j.bbrc.2007.08.160
   PubMed Web of Science ®Google Scholar
• Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 2009; 106:8368-73; PMID:19416831; http://dx.doi.org/10.1073/pnas.0903392106
   PubMed Web of Science ®Google Scholar
• Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J 2003; 22:537-47; PMID:12554654; http://dx.doi.org/10.1093/emboj/cdg038
   PubMed Web of Science ®Google Scholar
• Gauzzi MC, Barbieri G, Richter MF, Uze G, Ling L, Fellous M, Pellegrini S. The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. Proc Natl Acad Sci U S A 1997; 94:11839-44; PMID:9342324; http://dx.doi.org/10.1073/pnas.94.22.11839
   PubMed Web of Science ®Google Scholar
• Li Z, Gakovic M, Ragimbeau J, Eloranta ML, Ronnblom L, Michel F, Pellegrini S. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent. J Immunol 2013; 190:2335-44; PMID:23359498; http://dx.doi.org/10.4049/jimmunol.1203118
   PubMed Web of Science ®Google Scholar
• Potla R, Koeck T, Wegrzyn J, Cherukuri S, Shimoda K, Baker DP, Wolfman J, Planchon SM, Esposito C, Hoit B et al. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol Cell Biol 2006; 26:8562-71; PMID:16982690; http://dx.doi.org/10.1128/MCB.00497-06
   PubMed Web of Science ®Google Scholar
• Rani MR, Leaman DW, Han Y, Leung S, Croze E, Fish EN, Wolfman A, Ransohoff RM. Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem 1999; 274:32507-11; PMID:10542297; http://dx.doi.org/10.1074/jbc.274.45.32507
   PubMed Web of Science ®Google Scholar
• Ahmed CM, Noon-Song EN, Kemppainen K, Pascalli MP, Johnson HM. Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy. J Neuroimmunol 2013; 254:101-9; PMID:23110939; http://dx.doi.org/10.1016/j.jneuroim.2012.10.006
   PubMed Web of Science ®Google Scholar
• Prchal-Murphy M, Semper C, Lassnig C, Wallner B, Gausterer C, Teppner-Klymiuk I, Kobolak J, Muller S, Kolbe T, Karaghiosoff M et al. TYK2 kinase activity is required for functional type I interferon responses in vivo. PLoS One 2012; 7:e39141; PMID:22723949; http://dx.doi.org/10.1371/journal.pone.0039141
   PubMed Web of Science ®Google Scholar
• Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007; 7:703-14; PMID:17717540; http://dx.doi.org/10.1038/nri2154
   PubMed Web of Science ®Google Scholar
• Sojka DK, Plougastel-Douglas B, Yang L, Pak-Wittel MA, Artyomov MN, Ivanova Y, Zhong C, Chase JM, Rothman PB, Yu J et al. Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. Elife 2014; 3:e01659; PMID:24714492; http://dx.doi.org/10.7554/eLife.01659
   PubMed Web of Science ®Google Scholar
• Peng H, Jiang X, Chen Y, Sojka DK, Wei H, Gao X, Sun R, Yokoyama WM, Tian Z. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest 2013; 123:1444-56; PMID:23524967; http://dx.doi.org/10.1172/JCI66381
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-74; PMID:15771571; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115526
   PubMed Web of Science ®Google Scholar
• Sullivan RP, Leong JW, Fehniger TA. MicroRNA regulation of natural killer cells. Front Immunol 2013; 4:44; PMID:23450173; http://dx.doi.org/10.3389/fimmu.2013.00044
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 2007; 26:798-811; PMID:17540585; http://dx.doi.org/10.1016/j.immuni.2007.04.010
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9; PMID:21212348; http://dx.doi.org/10.1126/science.1198687
   PubMed Web of Science ®Google Scholar
• Ortaldo JR, Bere EW, Hodge D, Young HA. Activating Ly-49 NK receptors: central role in cytokine and chemokine production. J Immunol 2001; 166:4994-9; PMID:11290779; http://dx.doi.org/10.4049/jimmunol.166.8.4994
   PubMed Web of Science ®Google Scholar
• Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP et al. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology 2012; 1:1027-37; PMID:23170251; http://dx.doi.org/10.4161/onci.21284
   PubMed Web of Science ®Google Scholar
• Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000; 165:3571-7; PMID:11034357; http://dx.doi.org/10.4049/jimmunol.165.7.3571
   PubMed Web of Science ®Google Scholar
• Guan J, Miah SM, Wilson ZS, Erick TK, Banh C, Brossay L. Role of type I interferon receptor signaling on NK cell development and functions. PLoS One 2014; 9:e111302; PMID:25333658; http://dx.doi.org/10.1371/journal.pone.0111302
   PubMed Web of Science ®Google Scholar
• Robbins SH, Tessmer MS, Van Kaer L, Brossay L. Direct effects of T-bet and MHC class I expression, but not STAT1, on peripheral NK cell maturation. Eur J Immunol 2005; 35:757-65; PMID:15719366; http://dx.doi.org/10.1002/eji.200425797
   PubMed Web of Science ®Google Scholar
• Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, Straka E, Rigler D, Wallner B, Jamieson AM et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep 2013; 4:437-44; PMID:23933255; http://dx.doi.org/10.1016/j.celrep.2013.07.012
   PubMed Web of Science ®Google Scholar
• Wu X, Chen Y, Sun R, Wei H, Tian Z. Impairment of hepatic NK cell development in IFN-gamma deficient mice. Cytokine 2012; 60:616-25; PMID:22921904; http://dx.doi.org/10.1016/j.cyto.2012.07.012
   PubMed Web of Science ®Google Scholar
• Haan C, Rolvering C, Raulf F, Kapp M, Druckes P, Thoma G, Behrmann I, Zerwes HG. Jak1 has a dominant role over Jak3 in signal transduction through gammac-containing cytokine receptors. Chem Biol 2011; 18:314-23; PMID:21439476; http://dx.doi.org/10.1016/j.chembiol.2011.01.012
   PubMed Web of Science ®Google Scholar
• Trotta R, Chen L, Costinean S, Josyula S, Mundy-Bosse BL, Ciarlariello D, Mao C, Briercheck EL, McConnell KK, Mishra A et al. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood 2013; 121:3126-34; PMID:23422749; http://dx.doi.org/10.1182/blood-2012-12-467597
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol 2006; 176:1517-24; PMID:16424180; http://dx.doi.org/10.4049/jimmunol.176.3.1517
   PubMed Web of Science ®Google Scholar
• Luetke-Eversloh M, Cicek BB, Siracusa F, Thom JT, Hamann A, Frischbutter S, Baumgrass R, Chang HD, Thiel A, Dong J et al. NK cells gain higher IFN-gamma competence during terminal differentiation. Eur J Immunol 2014; 44:2074-84; PMID:24752800; http://dx.doi.org/10.1002/eji.201344072
   PubMed Web of Science ®Google Scholar
• Zhu S, Phatarpekar PV, Denman CJ, Senyukov VV, Somanchi SS, Nguyen-Jackson HT, Mace EM, Freeman AF, Watowich SS, Orange JS et al. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood 2014; 124:403-11; PMID:24891320; http://dx.doi.org/10.1182/blood-2013-05-499707
   PubMed Web of Science ®Google Scholar
• Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, Strobl B, Muller M, Sexl V. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood 2014; 124:2370-9; PMID:25185262; http://dx.doi.org/10.1182/blood-2014-03-564450
   PubMed Web of Science ®Google Scholar
• Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, Dorn GW, 2nd et al. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol 2013; 191:5904-13; PMID:24227772; http://dx.doi.org/10.4049/jimmunol.1301950
   PubMed Web of Science ®Google Scholar
• Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, Yu L, Butchar JP, Tridandapani S, Croce CM et al. miR-155 regulates IFN-gamma production in natural killer cells. Blood 2012; 119:3478-85; PMID:22378844; http://dx.doi.org/10.1182/blood-2011-12-398099
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Wylie T, Germino E, Leong JW, Magrini VJ, Koul S, Keppel CR, Schneider SE, Koboldt DC, Sullivan RP et al. Next-generation sequencing identifies the natural killer cell microRNA transcriptome. Genome Res 2010; 20:1590-604; PMID:20935160; http://dx.doi.org/10.1101/gr.107995.110
   PubMed Web of Science ®Google Scholar
• Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, Smyth MJ. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010; 184:902-11; PMID:20008292; http://dx.doi.org/10.4049/jimmunol.0903225
   PubMed Web of Science ®Google Scholar
• Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ, Colonna M. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008; 205:2965-73; PMID:19029380; http://dx.doi.org/10.1084/jem.20081752
   PubMed Web of Science ®Google Scholar
• Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res 2013; 73:4653-62; PMID:23761327; http://dx.doi.org/10.1158/0008-5472.CAN-12-4366
   PubMed Web of Science ®Google Scholar
• Zijlstra M, Bix M, Simister NE, Loring JM, Raulet DH, Jaenisch R. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature 1990; 344:742-6; PMID:2139497; http://dx.doi.org/10.1038/344742a0
   PubMed Web of Science ®Google Scholar
• Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5:112-7; PMID:1234049; http://dx.doi.org/10.1002/eji.1830050208
   PubMed Web of Science ®Google Scholar
• Kärre, K, Ljunggren, H G, Piontek, G, Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319:675–678. PMID 3951539; http//dx.doi.org/10.1038/319675a0
   Google Scholar
• Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A 2001; 98:11521-6; PMID:11562472; http://dx.doi.org/10.1073/pnas.201238598
   PubMed Web of Science ®Google Scholar
• Karaghiosoff M, Steinborn R, Kovarik P, Kriegshauser G, Baccarini M, Donabauer B, Reichart U, Kolbe T, Bogdan C, Leanderson T et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 2003; 4:471-7; PMID:12679810; http://dx.doi.org/10.1038/ni910
   PubMed Web of Science ®Google Scholar